Pelthos Therapeutics Inc. SEC filings PTHS
Pelthos Therapeutics Inc. has 253 filings in SEC EDGAR's recent list, going back to Sep 6, 2022. Its latest annual report, Form ARS, was filed on Aug 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (material agreement, new debt, unregistered share sale, change to shareholder rights, officer or director change, bylaw or fiscal year change, shareholder vote results, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 3, 2026 | — |
| 425 | Filing | Oct 30, 2026 | — |
| 425 | Filing | Oct 30, 2026 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Oct 30, 2026 | Oct 30, 2026 |
| 4 | Insider transaction | Oct 6, 2026 | Oct 2, 2026 |
| 4 | Insider transaction | Oct 6, 2026 | Oct 2, 2026 |
| 4 | Insider transaction | Oct 6, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 1, 2026 | Sep 29, 2026 |
| ARS | Annual report to shareholders | Aug 18, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Aug 18, 2026 | — |
| DEF 14A | Proxy statement | Aug 18, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q/A | Amended quarterly report | Aug 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Restatement
|
Aug 13, 2026 | Aug 12, 2026 |
| PRE 14A | Preliminary proxy statement | Aug 7, 2026 | Sep 29, 2026 |
| 4 | Insider transaction | Jul 7, 2026 | Jul 2, 2026 |
| 4 | Insider transaction | Jul 7, 2026 | Jul 2, 2026 |
| 4 | Insider transaction | Jul 7, 2026 | Jul 2, 2026 |
| 4 | Insider transaction | Jun 17, 2026 | Jun 15, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 28, 2026 | May 28, 2026 |
| 4 | Insider transaction | May 26, 2026 | May 22, 2026 |
| 144 | Notice of proposed sale | May 22, 2026 | — |
| 8-K |
Current report
Auditor change, Officer or director change
|
May 21, 2026 | May 15, 2026 |
| 4 | Insider transaction | May 18, 2026 | May 14, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 7, 2026 | — |
| 3 | Initial insider ownership | Apr 20, 2026 | Apr 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 14, 2026 | Apr 14, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 10, 2026 | Apr 10, 2026 |
| 4 | Insider transaction | Apr 6, 2026 | Apr 2, 2026 |
| 4 | Insider transaction | Apr 6, 2026 | Apr 2, 2026 |
| 4 | Insider transaction | Apr 6, 2026 | Apr 2, 2026 |
| 4 | Insider transaction | Apr 6, 2026 | Apr 2, 2026 |
| 4/A | Form 4/a | Apr 1, 2026 | Jun 14, 2024 |
| 4/A | Form 4/a | Apr 1, 2026 | Jun 14, 2024 |
| 4/A | Form 4/a | Apr 1, 2026 | Jun 14, 2024 |
| 4/A | Form 4/a | Apr 1, 2026 | Jul 2, 2025 |
| 4/A | Form 4/a | Apr 1, 2026 | Jul 2, 2025 |
| 4/A | Form 4/a | Apr 1, 2026 | Jul 2, 2025 |
| 4/A | Form 4/a | Apr 1, 2026 | Jul 2, 2025 |
| 4/A | Form 4/a | Apr 1, 2026 | Jul 2, 2025 |
| 4/A | Form 4/a | Apr 1, 2026 | Jul 2, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 19, 2026 | Mar 19, 2026 |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| 424B3 | Prospectus | Feb 13, 2026 | — |
| EFFECT | Filing | Feb 9, 2026 | — |
| CORRESP | Letter to the SEC | Feb 9, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 5, 2026 | — |
| S-3 | Shelf registration | Feb 2, 2026 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Jan 13, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 12, 2026 | Jan 6, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jan 2, 2026 | Dec 23, 2025 |
| 4 | Insider transaction | Dec 29, 2025 | Dec 23, 2025 |
| 3 | Initial insider ownership | Dec 29, 2025 | Dec 23, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Dec 23, 2025 | Dec 23, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 17, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Dec 17, 2025 | Dec 17, 2025 |
| 4 | Insider transaction | Dec 12, 2025 | Dec 10, 2025 |
| ARS | Annual report to shareholders | Dec 1, 2025 | Dec 31, 2024 |
| 4 | Insider transaction | Nov 26, 2025 | Nov 25, 2025 |
| DEF 14A | Proxy statement | Nov 25, 2025 | Dec 17, 2025 |
| D | Filing | Nov 19, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| PRE 14A | Preliminary proxy statement | Nov 14, 2025 | Nov 14, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 14, 2025 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 13, 2025 | Nov 13, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 4 | Insider transaction | Nov 10, 2025 | Nov 6, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 10, 2025 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Nov 7, 2025 | Nov 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2025 | Oct 14, 2025 |
| 424B3 | Prospectus | Sep 29, 2025 | — |
| EFFECT | Filing | Sep 24, 2025 | — |
| CORRESP | Letter to the SEC | Sep 24, 2025 | — |
| CORRESP | Letter to the SEC | Sep 19, 2025 | — |
| S-3/A | Filing | Sep 19, 2025 | — |
| 8-K/A |
Amended current report
Acquisition or sale of assets, Results of operations
|
Sep 16, 2025 | Sep 16, 2025 |
| UPLOAD | Letter from the SEC | Sep 5, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 3, 2025 | Sep 2, 2025 |
| S-3 | Shelf registration | Aug 28, 2025 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 18, 2025 | Aug 18, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2025 | — |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| S-8 | Employee stock plan registration | Jul 25, 2025 | — |
| 4 | Insider transaction | Jul 23, 2025 | Jul 2, 2025 |
| 3 | Initial insider ownership | Jul 23, 2025 | Jul 2, 2025 |
| 4 | Insider transaction | Jul 21, 2025 | Jul 2, 2025 |
| 3 | Initial insider ownership | Jul 21, 2025 | Jul 2, 2025 |
| D | Filing | Jul 10, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 8, 2025 | — |
| 4 | Insider transaction | Jul 7, 2025 | Jul 2, 2025 |
| 4 | Insider transaction | Jul 7, 2025 | Jul 2, 2025 |
| 4 | Insider transaction | Jul 7, 2025 | Jul 2, 2025 |
| 4 | Insider transaction | Jul 7, 2025 | Jul 2, 2025 |
| 4 | Insider transaction | Jul 7, 2025 | Jul 2, 2025 |
| 4 | Insider transaction | Jul 7, 2025 | Jul 2, 2025 |
| 4 | Insider transaction | Jul 7, 2025 | Jul 2, 2025 |
| 3 | Initial insider ownership | Jul 7, 2025 | Jul 1, 2025 |
| 3 | Initial insider ownership | Jul 7, 2025 | Jul 1, 2025 |
| 3 | Initial insider ownership | Jul 7, 2025 | Jul 1, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 3, 2025 | — |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Jul 3, 2025 | — |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| 3 | Initial insider ownership | Jul 3, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Other events
|
Jul 2, 2025 | Jul 1, 2025 |
| DEFM14C | Filing | May 27, 2025 | — |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| PREM14C | Filing | May 9, 2025 | May 9, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 1, 2025 | May 1, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Auditor change, Shareholder vote results, Regulation FD disclosure, Other events
|
Apr 17, 2025 | Apr 17, 2025 |
| 4 | Insider transaction | Apr 15, 2025 | Apr 11, 2025 |
| 4 | Insider transaction | Apr 15, 2025 | Apr 11, 2025 |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 3, 2025 | Feb 25, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 15, 2025 | — |
| EFFECT | Filing | Dec 19, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| POS AM | Filing | Dec 11, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2024 | — |
| EFFECT | Filing | Dec 2, 2024 | — |
| POS AM | Filing | Nov 22, 2024 | — |
| POS AM | Filing | Nov 22, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 21, 2024 | Nov 21, 2024 |
| 8-K12G3 | Filing | Nov 19, 2024 | Nov 18, 2024 |
| 8-K |
Current report
Material agreement, New debt, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change
|
Nov 18, 2024 | Nov 18, 2024 |
| 4 | Insider transaction | Nov 15, 2024 | Nov 13, 2024 |
| 4 | Insider transaction | Nov 15, 2024 | Nov 13, 2024 |
| 4 | Insider transaction | Nov 15, 2024 | Nov 13, 2024 |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 13, 2024 | — |
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 24, 2024 | Oct 22, 2024 |
| DEF 14A | Proxy statement | Sep 26, 2024 | Oct 22, 2024 |
| 4 | Insider transaction | Sep 16, 2024 | Sep 12, 2024 |
| 4 | Insider transaction | Sep 16, 2024 | Sep 12, 2024 |
| 4 | Insider transaction | Sep 12, 2024 | Sep 10, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 9, 2024 | Oct 22, 2024 |
| 424B3 | Prospectus | Aug 13, 2024 | — |
| 424B3 | Prospectus | Aug 13, 2024 | — |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Other events
|
Aug 7, 2024 | Aug 5, 2024 |
| EFFECT | Filing | Aug 6, 2024 | — |
| 424B3 | Prospectus | Aug 6, 2024 | — |
| D | Filing | Aug 6, 2024 | — |
| D | Filing | Aug 6, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 2, 2024 | — |
| S-1 | Registration statement | Jul 29, 2024 | — |
| 424B3 | Prospectus | Jul 29, 2024 | — |
| 424B3 | Prospectus | Jul 29, 2024 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure, Other events
|
Jul 29, 2024 | Jul 24, 2024 |
| 4 | Insider transaction | Jul 2, 2024 | Jun 28, 2024 |
| 3/A | Filing | Jul 2, 2024 | Feb 15, 2024 |
| 4/A | Filing | Jun 18, 2024 | Feb 21, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 424B3 | Prospectus | May 15, 2024 | — |
| 424B3 | Prospectus | May 15, 2024 | — |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| POS EX | Filing | Apr 17, 2024 | — |
| 424B3 | Prospectus | Apr 17, 2024 | — |
| 424B3 | Prospectus | Apr 17, 2024 | — |
| 10-K | Annual report | Apr 16, 2024 | Dec 31, 2023 |
| S-8 | Employee stock plan registration | Apr 15, 2024 | — |
| 8-K |
Current report
Other events
|
Apr 9, 2024 | Apr 9, 2024 |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Mar 18, 2024 | Mar 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 13, 2024 | Mar 13, 2024 |
| 4/A | Filing | Mar 12, 2024 | Feb 21, 2024 |
| SC 13G | Ownership over 5% (passive) | Mar 4, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Mar 1, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Mar 1, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Mar 1, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Mar 1, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Mar 1, 2024 | — |
| SC 13D | Ownership over 5% (active) | Feb 26, 2024 | — |
| 4 | Insider transaction | Feb 23, 2024 | Feb 21, 2024 |
| 4 | Insider transaction | Feb 23, 2024 | Feb 21, 2024 |
| 4 | Insider transaction | Feb 23, 2024 | Feb 21, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Feb 22, 2024 | Feb 15, 2024 |
| SEC STAFF LETTER | Filing | Feb 20, 2024 | — |
| 424B4 | Prospectus | Feb 20, 2024 | — |
| 424B4 | Prospectus | Feb 20, 2024 | — |
| POS EX | Filing | Feb 16, 2024 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PTHS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Durham, NC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1919246
- Former names
- Channel Therapeutics Corp (until May 27, 2025); Chromocell Therapeutics Corp (until Nov 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.